Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;93(10):5710-5711.
doi: 10.1002/jmv.27172. Epub 2021 Jul 8.

Immunostimulation with interferon-γ in protracted SARS-CoV-2 pneumonia

Anne-Claire Lukaszewicz  1   2 , Fabienne Venet  2   3   4 , Alexandre Faure  1 , Emmanuelle Vignot  5 , Guillaume Monneret  2   3
Affiliations
Comment

Immunostimulation with interferon-γ in protracted SARS-CoV-2 pneumonia

Anne-Claire Lukaszewicz et al. J Med Virol. 2021 Oct.
No abstract available

Keywords: SARS coronavirus < virus classification; antigen presentation < immune responses; immunodulators < disease control; immunomodulation < immune responses; inflammation < immune responses; interferon < antiviral agents.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Overtime evolution of virus detection, lymphocyte count, and mHLA‐DR in a COVID‐19 patient under immunotherapy. Black arrows at the bottom depict the timing of convalescent plasma (CP) therapy and IFN‐γ injections. Rapidly after IFN‐γ therapy onset, SARS‐CoV‐2 plasma mRNA decreased (black dashed line) while immune parameters rose up to reference values: lymphocyte count (blue dashed line, reference value >1000/mm3), mHLA‐DR (red line, reference value >13,500 AB/C). COVID‐19, coronavirus disease 2019; IFN, interferon; mHLA‐DR, low monocyte HLA‐DR expression; mRNA, messenger RNA; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2
See this image and copyright information in PMC

Comment on

References

    1. Gerber V, Velay A, Boehn L, et al. Protracted SARS‐CoV‐2 pneumonia with rituximab treatment: about two cases. J Med Virol. 2021;5:4141‐4144. 10.1002/jmv.26921 - DOI - PMC - PubMed
    1. Venet F, Cour M, Rimmelé T, et al. RICO study group. Crit Care. 2021;12 25(1):140. 10.1186/s13054-021-03558-w - DOI - PMC - PubMed
    1. Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterizes COVID‐19 infections. JCI Insight. 2020;3 5(17):e140329. 10.1172/jci.insight.140329 - DOI - PMC - PubMed
    1. Benlyamani I, Venet F, Coudereau R, Gossez M, Monneret G. Monocyte HLA‐DR measurement by flow cytometry in COVID‐19 patients: an interim review. Cytometry A. 2020;97(12):1217‐1221. 10.1002/cyto.a.24249 - DOI - PubMed
    1. Payen D, Faivre V, Miatello J, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019;5 19(1):931. 10.1186/s12879-019-4526-x - DOI - PMC - PubMed

Substances